Compare SPDR Gold Trust (GLD) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SPDR Gold Trust vs Pfizer Inc — how do they compare? SPDR Gold Trust trades at $384.46 (market cap $141.59B), while Pfizer Inc trades at $27.74 (market cap $159.59B). The key difference: SPDR Gold Trust and Pfizer Inc are close in size by market cap, and Pfizer Inc pays a 6.14% dividend while SPDR Gold Trust pays none. Which is the better fit depends on your goals — on Pluang, investors hold SPDR Gold Trust for 74 Days and Pfizer Inc for 158 Days on average.
| GLD | PFE | |
|---|---|---|
Market Cap | $141.59B | $159.59B |
Volume | 7,008,541 | 30,937,010 |
52-Week High | $495.90 | $29.02 |
52-Week Low | $362.32 | $23.67 |
Typical Hold Time | 74 Days | 158 Days |
Sector | — | Health |
Enterprise Value | — | $211.09B |
Dividend Yield | — | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLD is trading at $375.88, down 1.66% over the past 24 hours amid broader pressure from rising Treasury yields and a stronger U.S. dollar. The technical picture remains bearish with key support at $372 and resistance at $378. Recent news highlights gold's struggle to maintain momentum despite safe-haven demand, with weak payrolls data failing to spark a sustained rally.
The outlook for GLD remains challenged by persistent headwinds from elevated interest rates and dollar strength, though some analysts see tactical buying opportunities at current levels. Key risks include further Fed rate hikes and declining investor sentiment, while potential catalysts include geopolitical tensions and inflation concerns.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SPDR Gold Trust
GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
